Form 4: Sunshine Biopharma CEO Acquires and Disposes of Series B Preferred Stock
SEC Form 4 Filing
Steve N. Slilaty, CEO of Sunshine Biopharma, reports acquiring and disposing of Series B Preferred Stock on March 4, 2024.
Summary
- On March 4, 2024, Steve N. Slilaty, the CEO of Sunshine Biopharma, engaged in transactions involving Series B Preferred Stock.
- Slilaty acquired 100,000 shares of Series B Preferred Stock at a price of $0.1 per share.
- Following the acquisition, Slilaty disposed of 130,000 shares of Series B Preferred Stock.
- After these transactions, Slilaty beneficially owns 130,000 shares of Series B Preferred Stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company buy or sell the company's securities. This provides transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders may be interested in the CEO's transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction: acquisition and disposition of Series B Preferred Stock. |
| 03/05/2024 | Date of signature for the Form 4 filing. |
Keywords
Sunshine Biopharma, SBFM, Steve N. Slilaty, Series B Preferred Stock, Beneficial Ownership, Form 4, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.